Evidence map›Paper›PMID 33308291›Full record

Trial reportTrials2020

Vitamin D for prevention of sternotomy healing complications: REINFORCE-D trial.

Michal Čečrle, Dalibor Černý, Eva Sedláčková, Barbora Míková, Vlasta Dudková, Eva Drncová, Michala Pokusová, Ivo Skalský, Jana Tamášová, Milada Halačová

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Michal ČečrleDepartment of Clinical Pharmacy, Na Homolce Hospital, Prague, Czech Republic.
Dalibor ČernýDepartment of Clinical Pharmacy, Na Homolce Hospital, Prague, Czech Republic. dalibor.cerny@homolka.cz.ORCID http://orcid.org/0000-0001-8892-5996
Eva SedláčkováDepartment of Cardiac Surgery, Na Homolce Hospital, Prague, Czech Republic.
Barbora MíkováDepartment of Radiology, Na Homolce Hospital, Prague, Czech Republic.
Vlasta DudkováDepartment of Clinical Biochemistry, Hematology and Immunology, Na Homolce Hospital, Prague, Czech Republic.
Eva DrncováDepartment of Clinical Biochemistry, Hematology and Immunology, Na Homolce Hospital, Prague, Czech Republic.
Michala PokusováHospital Pharmacy, Na Homolce Hospital, Prague, Czech Republic.
Ivo SkalskýDepartment of Cardiac Surgery, Na Homolce Hospital, Prague, Czech Republic.
Jana TamášováDepartment of Medical Physics, Na Homolce Hospital, Prague, Czech Republic.
Milada HalačováDepartment of Clinical Pharmacy, Na Homolce Hospital, Prague, Czech Republic.
Na Homolce Hospital · CZCharles University · CZ

Funding

Ministerstvo Zdravotnictví Ceské Republiky IG 168 601Ministerstvo Zdravotnictví Ceské Republiky (CZ) Ig 168602Univerzita Karlova v Praze (CZ) SVV 260 263
6 · The paper itself

Abstract

backgroundMost cardiac surgery patients undergo median sternotomy during open heart surgery. Sternotomy healing is an arduous, very complex, and multifactorial process dependent on many independent factors affecting the sternum and the surrounding soft tissues. Complication rates for median sternotomy range from 0.5 to 5%; however, mortality rates from complications are very variable at 7-80%. Low calcidiol concentration below 80 nmol/L results in calcium absorptive impairment and carries a risk of bone loss, which is considered as a risk factor in the sternotomy healing process. The primary objective of this clinical trial is to compare the incidence of all postoperative sternotomy healing complications in two parallel patient groups administered cholecalciferol or placebo. The secondary objectives are focused on general patient recovery process: sternal bone healing grade at the end of the trial, length of hospitalization, number of days spent in the ICU, number of days spent on mechanical lung ventilation, and number of hospital readmissions for sternotomy complications.

methodsThis clinical trial is conducted as monocentric, randomized, double-blind, placebo-controlled, with planned enrollment of 600 patients over 4 years, approximately 300 in the placebo arm and 300 in the treatment arm. Males and females from 18 to 95 years of age who fulfill the indication criteria for undergoing cardiac surgery with median sternotomy can be included in this clinical trial, if they meet the eligibility criteria. DISCUSSION: REINFORCE-D is the first monocentric trial dividing patients into groups based on serum calcidiol levels, and with dosing based on serum calcidiol levels. This trial may help to open up a wider range of postoperative healing issues.

trial registrationEU Clinical Trials Register, EUDRA CT No: 2016-002606-39 . Registered on September 8, 2016.

Indexed as

Cardiac Surgical ProceduresSternotomyFemaleHumansMalePostoperative ComplicationsVitamin DWound HealingVitamin DCardiac surgeryCholecalciferolHealing complicationsRandomized clinical trialSternotomyTrial designVitamin D

Identifiers

PMID33308291
PMCPMC7731517
OpenAlexW3112309287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.